| Trial ID: | L6962 |
| Source ID: | NCT04276428
|
| Associated Drug: |
Ly3209590
|
| Title: |
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3209590|DRUG: Insulin Degludec
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through Day 85 | Secondary: Pharmacokinetics (PK): Area Under the Drug-Plasma-Concentration-Versus-Time Curve from Time Zero to 168 Hours Postdose (AUC[0-168]) of LY3209590, PK: AUC(0-168) of LY3209590, Predose on Day 1 through Day 85|Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose, PD: Change from Baseline in Fasting Plasma Glucose, Day 1 through Day 85
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2020-02-28
|
| Completion Date: |
2020-11-28
|
| Results First Posted: |
|
| Last Update Posted: |
2020-12-03
|
| Locations: |
Clinical Research Hospital Tokyo, Shinjuku-ku, Jp-13, 162-0053, Japan|P-one clinic, Hachioji, Tokyo, 192-0071, Japan|Yokohama Minoru Clinic, Yokohama, 232-0064, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT04276428
|
